Vectus Biosystems (ASX:VBS) Full Year 2024 Results

Key Financial Results

• Revenue: AU$1.14m (down 16% from FY 2023).

• Net loss: AU$2.34m (loss narrowed by 32% from FY 2023).

• AU$0.044 loss per share (improved from AU$0.072 loss in FY 2023).

VBS Products In Clinical Trials

• Phase I: 1.

All figures shown in the chart above are for the trailing 12 month (TTM) period

In the last 12 months, the only revenue segment was Medical Research and Development contributing AU$1.14m. The largest operating expense was General & Administrative costs, amounting to AU$2.26m (65% of total expenses). Explore how VBS's revenue and expenses shape its earnings.

Vectus Biosystems' share price is broadly unchanged from a week ago.

Risk Analysis

We should say that we've discovered 5 warning signs for Vectus Biosystems that you should be aware of before investing here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.